单唾液酸四己糖神经节苷脂对颅脑损伤患者血清中神经元特异性烯醇化酶的影响及其临床意义  

Effects of Ganglioside GM1 in Brain Injury Patients Serum Neuron Specific Enolase in Influence and Its Clinical Significance

作　　者：李计成[1] 李晓明[1] 戴如飞[1] 蔡军[1] 

机构地区：[1]徐州医学院第二附属医院神经外科,江苏省苏州市221006

出　　处：《实用心脑肺血管病杂志》2013年第2期36-38,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的探讨单唾液酸四己糖神经节苷脂(GM1)治疗中、重型颅脑损伤患者血清中神经元特异性烯醇化酶(NSE)的动态变化及其临床意义。方法将96例中、重型颅脑损伤患者随机分为GM1治疗组和常规治疗组,各48例,GM1治疗组急性期采用GM1治疗,常规治疗组行临床常规治疗,一般疗程为6周。所有患者治疗前及治疗后12h、24h、48h、72h、7d检测血清NSE水平,并于3个月后对患者预后进行评估。结果 GM1治疗组患者血清NSE水平在治疗后24h、48h、72h显著降低,与常规治疗组比较,差异均有统计学意义(P<0.05)。治疗后3个月,两组患者格拉斯哥预后评分(GOS)比较,差异有统计学意义(P<0.05)。结论 GM1治疗可以减轻神经元损伤,显著抑制NSE释放,增强神经元对损伤的耐受性,对中、重颅脑损伤患者具有保护作用。Objective To study Ganglioside （ GM1 ） in the treatment of severe brain injury patients, the serum neuron specific enolase （NSE） dynamic changes and its clinical significance. Methods In 96 cases, patients with severe craniocerebral injury were randomly divided into GMI group and routine treatment group, 48 cases in each group, GM1 treatment in acute phase using GM1 treatment, conventional treatment group of clinical routine treatment, general treatment for 6 weeks. All patients before treatment and after treatment of 12h, 24h, 48h, 72h, 7d to detect serum NSE levels, and after 3 months on prognosis of patients undergoing assessment. Results GM1 treatment group, serum NSE levels after treatment in 24h, 481i, 72h were significantly decreased, compared with conventional treatment group, the difference was statistically significant （P 〈 0. 05 ）. After 3 months of treatment, two groups of patients with the Glasgow outcome score （ GOS）, the difference was statistically significant （P 〈0. 05）. Conclusion GM1 can alleviate neuronic damage, restrain neuronic NSE release and enhance the tolerance of brain cell. GM1 has a protective effect for moderate and severe brain injury.

关 键 词：颅脑损伤 神经节苷脂类 磷酸丙酮酸水合酶 

分 类 号：R651.15[医药卫生—外科学]